DelveInsight
DelveInsight's primary conduit for delivering intelligent information to professionals in both the business and healthcare sectors is through its meticulously crafted analytical and strategic reports. Presently, DelveInsight boasts a diverse portfolio encompassing over 3,000 Marketed and Pipeline Reports. These reports are thoughtfully categorized based on parameters such as indication, mechanism of actions, drugs, global API manufacturers, and specialized reports focusing on pivotal areas such as Onco-Immunology, Orphan Diseases, Biologics & Biosimilars, Gene Therapy, Stem Cells Therapy, and other emerging domains. This robust platform has become the go-to resource for numerous enterprises seeking to transform and redefine their business strategies.
DelveInsight's offerings extend beyond reports to encompass Consulting Projects and Competitive Intelligence services, catering to the multifaceted needs of its clientele. Moreover, the organization is dedicated to providing tailor-made research services that align with the specific interests and requirements of its clients. DelveInsight's commitment to excellence and innovation positions it as a trusted partner in the areas of business strategy and market research.
View recent articles by this publisher on our blog:
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
The Power of Digital Therapeutics in Mental Health
Anti-VEGF Therapies: Forever Market Rulers of Wet-AMD Treatment?
Additional articles from this publisher
9,388 Reports from DelveInsight
-
Chronic Spontaneous Urticaria - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s analysis, the Chronic Spontaneous Urticaria Market Size in the 7MM was valued at approximately USD 2,173.3 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a CAGR of more than 10%, driven by the introduction o ... Read More
-
Acromegaly- Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to the estimates, the Acromegaly market size in the 7MM is ~USD 1,300 million in 2023. In 2023, among all the therapies, the highest Acromegaly market revenue was generated by somatostatin, i.e., ~USD 300 million, followed by growth hormone antagonist, i.e., ~USD 90 million ... Read More
-
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the 7MM reported approximately 15,840 thousand diagnosed prevalent cases of Alzheimer’s disease, reflecting a significant disease burden. This high prevalence underscores the need for innovative treatments to address the rising impact on healthcare systems and patient care. I ... Read More
-
Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the US accounted for the maximum share of the Ewing sarcoma Treatment Market in the 7MM, i.e., nearly 53%. A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because most Ewing sarcoma Patients are under 20 years old. Although there is no st ... Read More
-
Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the market size of epidermolysis bullosa was highest in the US among the 7MM, accounting for approximately USD 1,300 million, which is further expected to increase by 2034. Epidermolysis bullosa simplex (EBS) is the least severe type of epidermolysis bullosa, and many individ ... Read More
-
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The heparin-induced thrombocytopenia market size in the 7MM is estimated to be around ~USD 128 million, in 2023. Heparin-induced thrombocytopenia is characterized by a rapid decrease in platelet count occurring 5–14 days after the initiation of heparin therapy. It is primarily caused ... Read More
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
Key Highlights Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2023, accounting for nearly 70% of the total KRAS Inhibitor market share. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenu ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of n ... Read More
-
Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights The Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023. Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Market Size of ~USD 25 Million in 2023. Among the seven major countries, the Postpartum Depression diagn ... Read More
-
4-1BB receptor Agonist - Pipeline Insight, 2025
DelveInsight’s, “4-1BB receptor Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in 4-1BB receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers t ... Read More
-
5-HT2 Agonist - Pipeline Insight, 2025
DelveInsight’s, “5-HT2 Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in 5-HT2 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics as ... Read More
-
5-HT4 Antagonist - Pipeline Insight, 2025
“5-HT4 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2025
“5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) deve ... Read More
-
Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025
DelveInsight’s, “Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclin ... Read More
-
Adenosine A3 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
Akt1 Inhibitor - Pipeline Insight, 2025
“Akt1 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Akt1 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ... Read More
-
Aldose Reductase Inhibitor - Pipeline Insight, 2025
“Aldose Reductase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Aldose Reductase Inhibitor development. The report provides detailed coverage of the pipeline landscape for ... Read More
-
Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025
“Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3/5/6 Integrin Antagonist development. The report provides detailed coverage of th ... Read More
-
Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025
“Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3 Integrin Antagonist development. The report provides detailed coverage of the pipeli ... Read More
-
AMPA Receptor Antagonist - Pipeline Insight, 2025
“AMPA Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across AMPA Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Anti-CD19 Antibody - Pipeline Insight, 2025
DelveInsight’s, “Anti-CD19 Antibody - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Anti-CD19 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the thera ... Read More
-
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025
DelveInsight’s, “Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also c ... Read More
-
Anti-CD80 Antibody - Pipeline Insight, 2025
“Anti-CD80 Antibody - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD80 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
ATPase Inhibitor - Pipeline Insight, 2025
“ATPase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across ATPase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
Beta-1 Receptors Antagonist - Pipeline Insight, 2025
“Beta-1 Receptors Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Beta-1 Receptors Antagonist development. The report provides detailed coverage of the pipeline landscape f ... Read More
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook